NCT00098228
Completed
Phase 2
Dose-Ranging Study in Patients With COPD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- COPD
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 686
- Locations
- 54
- Primary Endpoint
- Pulmonary function measured between 22 and 24 hours after dosing on Day 1
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
The trial is designed to identify an appropriate dose of QAB149 for delivery via a multiple dose inhaler for use in the COPD Phase III program.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of COPD
- •Age 40-75 years
- •Smoking history
Exclusion Criteria
- •Other serious disease
- •Allergy to QAB149
- •Respiratory tract infection
Outcomes
Primary Outcomes
Pulmonary function measured between 22 and 24 hours after dosing on Day 1
Secondary Outcomes
- Safety measurements
- Pulmonary function measured on days 1 and 7 at various intervals after dosing
Study Sites (54)
Loading locations...
Similar Trials
Completed
Phase 2
Study in Patients With COPDCOPDNCT00215384Dey35
Completed
Phase 2
Study in Patients With COPDCOPDChronic Obstructive Pulmonary DiseaseNCT00215423Dey49
Completed
Phase 3
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) ExacerbationsChronic Obstructive Pulmonary DiseaseNCT01120691Novartis Pharmaceuticals2,224
Completed
Phase 4
Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient CohortCOPDNCT02516592Novartis Pharmaceuticals500
Completed
Phase 2
Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)NCT00570778Novartis Pharmaceuticals154